Session Information
Session Type: Poster Session B
Session Time: 10:30AM-12:30PM
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate to severe plaque psoriasis. Deucravacitinib was efficacious vs placebo and apremilast in patients with moderate to severe plaque psoriasis in two 52-week, global, phase 3 trials, POETYK PSO-1 and POETYK PSO-2, and through 4 years in the ongoing open-label POETYK long-term extension (LTE) trial. The current analysis evaluated deucravacitinib efficacy through 4 years in patient subgroups defined by prior use of biologic therapy for the treatment of psoriasis.
Methods: Response rates for ≥ 75%/≥ 90% reduction from baseline in Psoriasis Area and Severity Index score (PASI 75/90) and static Physician Global Assessment score of 0 (clear) or 1 (almost clear) (sPGA 0/1) were evaluated in patients who received continuous deucravacitinib treatment from baseline (day 1) through 4 years (week 208; data cutoff, November 1, 2023) based on prior biologic therapy use, including anti-interleukin (IL) therapy (anti–IL-17, anti–IL-23, anti–IL-12/23p40) and anti–tumor necrosis factor (TNF) therapy. Response rates were compared with long-term response rates previously reported in the overall study population. Modified nonresponder imputation (mNRI) was used to impute missing data.
Results: In total, 513 patients received continuous deucravacitinib treatment from baseline. A total of 508 patients met the criteria for the mNRI analysis. Of the 513 patients, 37.2% had received prior biologic therapy (anti-IL, 24.2%; anti-TNF, 15.4%). PASI 75 responses were maintained from week 52 in the parent trials (72.0%) through 4 years in the overall population (71.7%), with slightly lower response rates in patients with vs without prior biologic therapy (any biologic, 65.9% vs 75.1%; prior anti-IL, 63.6% vs 74.3%; prior anti-TNF, 65.2% vs 72.9%, respectively). In addition, PASI 90 responses were maintained at similar rates through 4 years in each population (overall, 47.5%; any biologic, 45.9% vs 48.5%; anti-IL, 42.7% vs 49.1%; anti-TNF, 46.0% vs 47.8%) as were sPGA 0/1 responses (overall, 57.2%; any biologic, 57.8% vs 56.8%; anti-IL, 54.8% vs 57.9%; anti-TNF, 62.0% vs 56.3%).
Conclusion: Deucravacitinib treatment maintained high efficacy rates through 4 years in patients with plaque psoriasis regardless of prior use of biologic therapy, including anti-IL therapy and anti-TNF therapy. These findings provide additional support that deucravacitinib, a once-daily oral drug, is an efficacious therapeutic option through 4 years in patients with plaque psoriasis regardless of prior use of biologics, including anti-IL therapies that target similar pathways as TYK2 inhibition (eg, IL-23/IL-17).
To cite this abstract in AMA style:
Warren R, Armstrong A, Imafuku S, Morita A, Paul C, Augustin M, Passeron T, Kircik L, Vritzali E, Scharnitz T, Schroeder G, Banerjee S, Strober B. Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/deucravacitinib-in-plaque-psoriasis-4-year-efficacy-results-by-prior-biologic-treatment-in-the-phase-3-poetyk-pso-1-pso-2-and-long-term-extensiontrials/. Accessed .« Back to ACR Convergence 2024
ACR Meeting Abstracts - https://acrabstracts.org/abstract/deucravacitinib-in-plaque-psoriasis-4-year-efficacy-results-by-prior-biologic-treatment-in-the-phase-3-poetyk-pso-1-pso-2-and-long-term-extensiontrials/